Status:
COMPLETED
A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin
Lead Sponsor:
Bayer
Conditions:
Lymphoma, Follicular
Non-Hodgkin Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this study is to compare hematological toxicity, costs, health-related quality of Life (HR-QOL) and outcomes observed in real life in the Belgian Non-Hodgkin Lymphoma (NHL) population...
Eligibility Criteria
Inclusion
- Advanced cancer of the lymph nodes of follicular type at study inclusion
- The patient has relapsed or has refractory disease, after previous treatment with rituximab
- Treating physician has decided to treat the patient with a 90Y-Zevalin regimen
- The patient is \>= 18 years of age
- Patient has given informed consent
Exclusion
- Patient is unwilling or unable to give informed consent
- Patient is participating in another clinical trial
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2009
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01164696
Start Date
August 1 2007
End Date
May 1 2009
Last Update
August 24 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Belgium